Last updated on November 2019

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy Surgery and/or Radiation Therapy


Brief description of study

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

Detailed Study Description

This is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily) in early stage node-positive HER2 negative breast cancer patients. Patients will be randomized 1:1 within stratum defined by: Hormone Receptor status (HR positive vs HR negative), body mass index (<30 vs 30 kg/m2) and stage (Stage II vs III).

The primary objective of this trial is to compare the effect of aspirin versus placebo upon invasive disease free survival (iDFS).

Primary objective To compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients.

Secondary objectives

  1. To compare the effect of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients upon:
  2. Distant disease-free survival
  3. Overall survival
  4. Cardiovascular disease (see Section11.3)
  5. To compare the toxicity of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients.
  6. To assess adherence to aspirin and placebo among early stage node-positive HER2 negative breast cancer patients.
  7. To bank tumor and germline deoxyribonucleic acid (DNA), plasma and urine collected at baseline and sequential plasma and urine collected 2 years later for future measurement of inflammatory markers.
  8. To determine if there are subgroups of participants characterized by lifestyle factors associates with greater inflammation for whom there is greater benefit of aspirin versus placebo upon iDFS.

Patients are followed up to 10 years after study enrollment.

Clinical Study Identifier: NCT02927249

Find a site near you

Start Over

Michigan Cancer Specialists

Roseville, MI United States
  Connect »

Advanced Breast Care Center PLLC

Warren, MI United States
2.44miles
  Connect »

Macomb Hematology Oncology PC

Warren, MI United States
3.06miles
  Connect »

Michigan Breast Specialists-Warren

Warren, MI United States
3.06miles
  Connect »

Saint John Macomb-Oakland Hospital

Warren, MI United States
3.06miles
  Connect »

Bhadresh Nayak MD PC-Sterling Heights

Sterling Heights, MI United States
5.05miles
  Connect »

Premier Hematology Oncology Care

Sterling Heights, MI United States
5.05miles
  Connect »

Ascension Saint John Hospital

Detroit, MI United States
5.61miles
  Connect »

Academic Hematology Oncology Specialists

Grosse Pointe Woods, MI United States
5.61miles
  Connect »

Michigan Breast Specialists-Grosse Pointe Woods

Grosse Pointe Woods, MI United States
5.61miles
  Connect »

McLaren Cancer Institute-Macomb

Mount Clemens, MI United States
7.13miles
  Connect »

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, MI United States
8.18miles
  Connect »

William Beaumont Hospital-Grosse Point

Grosse Pointe, MI United States
8.23miles
  Connect »

Mitchell Folbe MD PC

Sterling Heights, MI United States
8.97miles
  Connect »